Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers

Scientific Institute for Research Hospitalization and Healthcare (IRCCS)

Status

Enrolling

Conditions

Endometrial Cancer

Breast Cancer Metastatic

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Ovarian Cancer

Cervical Carcinoma

Treatments

Drug: Oncologic drugs administered for treatment of breast cancer

Drug: Oncologic drug administered for treatment of gynecologic cancer

Study type

Observational

Funder types

Other

Identifiers

NCT06800612

STRATEGIA

Details and patient eligibility

About

retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.

Full description

This is a single-center retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.

Regarding the prospective component of the study, it is clarified that therapy will be warranted by clinical practice regardless of study enrollment. Diagnostic investigations will also be conducted as per normal practice; enrollment in the study does not require additional examinations.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic;
Patients who have received treatment for breast cancer or gynecologic cancer since January 2010;
Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data.

Exclusion criteria